Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 5, 2013, Pages 1143-1147

  Tawbi, Hussein A ^a,b   Tran, An L ^b   Christner, Susan M ^a   Lin, Yan ^c   Johnson, Matthew ^a   Mowrey, Emily ^a   Appleman, Leonard R ^b   Stoller, Ronald ^b   Miller, Brian M ^a   Egorin, Merrill J ^a,b   Beumer, Jan H ^a,d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Calcium; CML; Interaction; Nilotinib

Indexed keywords

ANTIEMETIC AGENT; CALCIUM CARBONATE; IMATINIB; NILOTINIB; TUMS ULTRA 1000; UNCLASSIFIED DRUG; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTACID AGENT; ANTINEOPLASTIC AGENT; CALCIUM INTAKE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ACNE; ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; BODY MASS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CALCIUM INTAKE; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; FOOD DRUG INTERACTION; GASTRITIS; HALF LIFE TIME; INTESTINE ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; STOMACH MUCOSA;

ADMINISTRATION, ORAL; ADULT; ANTACIDS; ANTINEOPLASTIC AGENTS; CALCIUM CARBONATE; CALCIUM, DIETARY; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; FEMALE; FOOD-DRUG INTERACTIONS; GASTRIC MUCOSA; GASTRITIS; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84887210795     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2283-x     Document Type: Article

References (15)

1. Saglio G, Kim DW, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259
2. Kantarjian HM, Hochhaus A, Saglio G, De SC, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841-851
3. Cho JH, Kim KM, Kwon M, Kim JH, Lee J (2011) Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 30(5):2008-2014
4. Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, Kakeji Y, Onozawa Y, Yamasaki M, Ohtsu A (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117(20):4633-4641
5. Ravaud A, Bello CL (2011) Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: maintaining optimum efficacy in clinical practice. Anticancer Drugs 22:377-383
6. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022-4028
7. Demetri GD, Wang Y, Wehrle E, Blanke C, Joensuu H, von Mehren M (2008) Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST). In: ASCO gastrointestinal cancers symposium
8. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551 (Pubitemid 43882350)
9. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF (2004) Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 160:339-349 (Pubitemid 39045265)
10. Straub DA (2007) Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 22:286-296
11. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, KM U, Staten AM, Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935-942 (Pubitemid 34520420)
12. Parise RA, Egorin MJ, Christner SM, Shah DD, Zhou W, Beumer JH (2009) A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. J Chromatogr B Analyt Technol Biomed Life Sci 877:1894-1900
13. de Campos DR, Vieira NR, Bernasconi G, Barros FA, Meurer EC, Marchioretto MA, Coelho EC, Calafatti SA, Sommer C, Couto JM, Buranello S, Silva AR, Amarante AR, Abib E, Junior JP (2007) Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. Arzneimittelforschung 57:309-314 (Pubitemid 47055998)
14. Sparano BA, Egorin MJ, Parise RA, Walters J, Komazec KA, Redner RL, Beumer JH (2009) Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 63:525-528
15. Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, Schran H (2010) Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 50:960-967